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The genetic heterogeneity of cancer influences the trajectory of tumor progression and may underlie clinical
variation in therapy response. To model such heterogeneity, we produced genetically and pathologically accurate
mouse models of common forms of human acute myeloid leukemia (AML) and developed methods to mimic
standard induction chemotherapy and efficiently monitor therapy response. We see that murine AMLs harboring
two common human AML genotypes show remarkably diverse responses to conventional therapy that mirror
clinical experience. Specifically, murine leukemias expressing the AML1/ETO fusion oncoprotein, associated with
a favorable prognosis in patients, show a dramatic response to induction chemotherapy owing to robust activation
of the p53 tumor suppressor network. Conversely, murine leukemias expressing MLL fusion proteins, associated
with a dismal prognosis in patients, are drug-resistant due to an attenuated p53 response. Our studies highlight the
importance of genetic information in guiding the treatment of human AML, functionally establish the p53
network as a central determinant of chemotherapy response in AML, and demonstrate that genetically engineered
mouse models of human cancer can accurately predict therapy response in patients.
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Cancer arises as a consequence of accumulating genetic
lesions in proto-oncogenes and tumor suppressor genes,
which impact primary pathology and trajectory of in-
dividual tumors and ultimately dictate their response to
therapy. Cancer genomes are complex and heteroge-
neous, and it is this genetic heterogeneity that underlies
the variable responses of individual patients to therapy,
even within the same pathological cancer type. It follows
that a better understanding of these genotype–response
relationships will enable a more effective use of estab-
lished regimens and guide the development and evalua-
tion of new therapeutic agents.
Acute myeloid leukemia (AML) is a malignant disorder
of progenitor cells in myeloid hematopoiesis and exem-
plifies a genetically heterogeneous cancer. To date, >100
genetic aberrations have been implicated in this disease.
The emergence of AML is thought to require cooperation
between proproliferative mutations typically involving
Ras signaling pathways and defects in myeloid differen-
tiation, which often result from chromosomal transloca-
tions (Gilliland et al. 2004). Numerous clinical studies
have assessed frequency and co-occurrence as well as
pathological and clinical associations of common muta-
tions in AML (for review see, Estey and Dohner 2006).
While most of these data sets are limited to selected
candidate genes, recent advances in genome analysis now
allow for a comprehensive survey of leukemia oncoge-
nomes (Mullighan et al. 2007; Ley et al. 2008).
Patients with AML show a heterogeneous response to
therapy. The current ‘‘standard of care’’ for AML patients
involves an initial phase of intense chemotherapy (in-
duction) followed by post-remission treatment including
additional chemotherapy cycles and/or allogeneic stem
cell transplantation. The combination of cytarabine (cy-
tosine arabinoside, Ara-C) with an anthracycline is the
backbone of induction therapy; nevertheless, treatment
responses and outcome to this regimen vary from primary
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refractory disease to cure (Estey and Dohner 2006).
In addition to patient age, disease etiology, and initial
response to therapy, certain mutations have been associ-
ated with favorable, average, or adverse treatment out-
come (Grimwade et al. 1998; Byrd et al. 2002; Schlenk
et al. 2008). For example, deletions of chromosomes 5q
and 7q and certain 11q23 rearrangements resulting in
MLL fusion proteins are associated with adverse therapy
response (for review, see Estey and Dohner 2006). On the
contrary, translocations t(8;21) and t(16;16)/inv(16),
resulting in expression of the anti-differentiation fusion
proteins AML1/ETO and CBFb/MYH11, respectively, are
associated with a favorable outcome (Grimwade et al.
1998). Despite these associations, the use of genotypic
information to guide treatment decisions has only re-
cently entered into clinical practice, and not in any
standardized way.
A better understanding of how cancer genotypes in-
fluence treatment outcome in AML and other cancers
will undoubtedly improve the use of existing drugs
and facilitate the development of more effective thera-
pies. Genetic analysis of human AML has provided
valuable correlative data, yet the complexity of AML
genomes complicates its use in predicting treatment
response (Dohner 2007). In contrast, functional studies
enable a cause-and-effect relationship between particular
genes and treatment response, but can be confounded by
the lack of predictive experimental systems. Human-
derived cancer cell lines, while useful in high-throughput
drug screening, are often poorly defined at the genotypic
level and fail to engage the microenvironment, which has
decisive roles in both tumorigenesis (Wei et al. 2008) and
therapy response (Schmitt et al. 2000). As a consequence,
it has been debated whether such systems are accurate
predictors of drug action in patients. On the other hand,
genetically engineered mouse models enable the study of
drug action in a physiological environment and thereby
provide a means to dissect the relationship between
complex disease genetics and therapy response in a way
that is not possible in humans. However, potential differ-
ences in drug behavior, as well as the technical challenges
associated with animal studies, have made it difficult to
determine whether these models accurately mirror treat-
ment behavior in the clinic.
In this study, we use AML as a model cancer type
to study the genotype–response relationship of geneti-
cally defined murine cancers to frontline chemotherapy.
We exploited information on genetic lesions occurring
together in human leukemias to generate new models of
common AML genotypes, established an induction che-
motherapy protocol for mice, and integrated sensitive
imaging methods to monitor leukemia response in vivo.
We then used these tools to characterize genotype–
response relationships in AML and to explore the un-
derlying molecular basis for these effects. Our studies
provide insights into the differential response patterns
of human leukemia, suggest strategies for improving
the use of conventional chemotherapy, and produce
tractable preclinical systems for testing new therapeutic
approaches.
Results
Oncogenic Ras cooperates with anti-differentiation
fusion proteins to produce AML
To generate mouse models that reflect common genetic
themes in human AML, we examined a new data set of
111 pediatric AML cases that integrates conventional
karyotyping, genome-wide SNP array analysis, and de-
tailed sequencing data for 21 oncogenes and tumor
suppressors (I. Radtke and J.R. Downing, unpubl.). Most
cases harbored, on average, mutations in two known
oncogenes or tumor suppressor genes, which occurred
in various combinations. Among the most common
karyotype aberrations were translocations producing
AML1/ETO (n = 20), CBFB/MYH11 (n = 16), and MLL
rearrangements (n = 17). Remarkably, all three trans-
locations were most commonly associated with activat-
ing mutations in NRAS that were detected in 45%, 44%,
and 24% of the cases, respectively (Fig. 1A). Consistent
with previous reports on adult AML, patients harboring
leukemias containing AML1/ETO or CBFB/MYH11 fu-
sion genes showed an improved response to therapy and
better clinical course than those harboring MLL fusions
(Fig. 1B). Based on these findings, together with studies
indicating that anti-differentiation and proproliferative
genes cooperate to promote AML in mice (Kelly et al.
2002; Ono et al. 2005), we reasoned thatmouse leukemias
coexpressing either AML1/ETO or MLL/ENL together
with oncogenic Nras would provide accurate yet distinct
models of human AML associated with dramatically
different clinical outcomes.
To rapidly generate mice harboring leukemias with
various genetic alterations, we applied a ‘‘mosaic’’ ap-
proach involving retroviral transduction of oncogenes
into hematopoietic stem and progenitor cells, followed
by retransplantation of the genetically altered cells into
syngeneic recipients (Fig. 1D). This strategy enables
multiple oncogenes and reporter elements to be intro-
duced in a one-step procedure, thereby facilitating disease
monitoring and reducing the animal husbandry associ-
ated with germline transgenic mice. To model trans-
location (8;21), we choose to express the AML1/ETO9a
splice variant that is expressed in the majority of t(8;21)
patients and has increased leukemogenic potential in
mice (Yan et al. 2006; Lafiura et al. 2008). To model
MLL translocations, we used theMLL/ENL variant that is
among the most common and associated with a particu-
larly poor prognosis (Schoch et al. 2003). Both fusion
genes were coexpressed with enhanced green fluorescent
protein (EGFP) in bicistronic constructs (Fig. 1C). Onco-
genic NrasG12D was coexpressed with luciferase to enable
imaging of the resulting leukemias by bioluminescence.
Of note, NrasG12D was cloned downstream from an
internal ribosomal entry site (IRES), which reduces ex-
pression of the ectopic Nras gene to near physiological
levels (Parikh et al. 2006).
Each oncogene was introduced alone or in combi-
nation into fetal liver cells (FLCs) derived from embry-
onic day 13.5–15 (E13.5–E15) embryos, and the infected
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populations—which are highly enriched for hematopoietic
stem and progenitor cells (Morrison et al. 1995)—were
used to reconstitute the hematopoietic compartment of
lethally irradiated syngeneic recipient mice (Fig. 1D).
Recipient animals were then monitored for disease onset
by analysis of peripheral blood and bioluminescence for
Figure 1. Generation of genetically defined
mosaic mouse models based on common
genetic associations in human AML. (A) Fre-
quency of Nras mutations in 111 cases of
pediatric AML in major karyotype groups.
Asterisks indicate significant association in
multifactor dimensionality reduction analysis
(Ritchie et al. 2001). (B) Kaplan-Meier plot
showing the overall survival of pediatric
AML patients treated after 1998 depending
on major karyotype group, including t(8;21) =
AML1/ETO (n = 10), inv(16)/t(16;16) = CBFB/
MYH11 (n = 9), and 11q23/MLL rearrange-
ments (n = 9) compared with other subtypes
(n = 22, excluding patients with PML/RARa
positive AML). The presence of AML1/ETO
and MLL fusion proteins has opposite effects
on long-term therapy outcome. In an indepen-
dent analysis using the same data set, Nras
mutations were associated with a slightly
better 5-yr survival with low-statistic signifi-
cance (5-yr survival 79.4 vs. 50.4%, P = 0.09).
(C) MSCV-based retroviral constructs used to
coexpress AML oncogenes with fluorescent
and bioluminescent markers. (D) Schematic
overview of mosaic AML mouse models.
Wild-type C57BL/6 FLCs isolated at E13.5–E15
were (co)transduced with oncogenic retrovi-
ruses and used to reconstitute the hematopoi-
etic system of lethally irradiated recipientmice.
(E) Mice reconstituted with FLCs transduced
with the indicated transgenes were monitored
for illness for 180 d and died or were euthanized
at a terminal disease stage. The data are pre-
sented in a Kaplan–Meier format showing the
percentage of mouse survival at various time
points post-transplantation. Five recipients of
FLCs transduced with Nras only were followed
up further; three succumbed to leukemias after
212, 287, and 292 d, likely after accumulating
additional lesions. (F) Luciferase imaging of re-
cipient mice of FLCs transduced with the in-
dicated genes at 14, 21, and 42 d following
transplantation. Transduction of Luciferase-
IRES-Nras rapidly induces onset of Luciferase-
positive disease only in concert with AML1/
ETO9a or MLL/ENL. (G) Expression analysis of
retroviral oncogenes in wild-type bone marrow
(wt bm) and independent primary AMLs (1–3)
with indicated genotypes. Expression of human
AML1/ETO9a and MLL/ENL transcripts was
verified by RT–PCR using fusion site-specific
primers. Reverse transcriptase free control reac-
tions were negative in all samples (data not
shown). Western blot analysis using pan-Ras
and Nras-specific antibodies demonstrating
Nras overexpression in leukemia lysates derived from Nras-cotransduced FLCs. Overall Ras levels (pan-Ras) do not show significant
elevation. (H) Baseline phospho-Erk levels are strongly elevated in leukemias deriving from Nras-cotransduced FLCs. Levels of
phosphorylated Erk were measured using phospho-specific flow cytometry in wild-type whole bone marrow and GFP-positive MLL/ENL,
MLL/ENL +Nras, and AML1/ETO9a +Nras leukemias. Representative histograms are shown.
Mouse models of human AML therapy
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the transduced luciferase reporter. As expected, mice
receiving FLCs expressing AML1/ETO9a or MLL/ENL
alone eventually developed GFP-positive leukocytosis
consistent with peripheral leukemia. The survival of
these animals was similar to previous reports, with
AML1/ETO9a inducing leukemia with a longer latency
compared with MLL/ENL (170 vs. 48 d median survival,
P < 0.0001).
Although NrasG12D was not oncogenic on its own, it
cooperated with both AML1/ETO9a and MLL/ENL to
accelerate leukemia onset and reduce overall survival
(170 d to 84 d for AML1/ETO9a, P = 0.0026; 48 d to 24
d for MLL/ENL, P < 0.0001) (Fig. 1E). Of note, leukemias
arising from FLCs transduced with both retroviral vectors
were invariably positive for both luciferase (Fig. 1F) and
GFP (data not shown), suggesting a strong selective
advantage for cells harboring a fusion protein together
with Nras. Indeed, the resulting leukemias expressed the
expected transgenes (Fig. 1G), and those harboring acti-
vated Nras displayed hyperactive mitogen-activated pro-
tein kinase (Mapk) signaling as assessed by flow
cytometry for phospho-Erk (a downstream Ras effector
in the Mapk cascade) (Fig. 1H). Thus, lesions that occur
together in human AML cooperate to rapidly generate
leukemia in mice.
Murine leukemias display pathological features
of human AML
In human patients, AML is characterized by the appear-
ance of malignant myeloid progenitors, which rapidly
accumulate in bone marrow and aggressively infiltrate
extramedullary tissues. Mice harboring leukemias coex-
pressing either AML1/ETO9a or MLL/ENL together with
oncogenic Nras displayed progressive anemia and leuko-
cytosis (Fig. 2A), with extensive hepatosplenomegaly
(data not shown). Upon reaching a terminal stage, GFP-
positive cells dominated their peripheral blood, bone
marrow, spleen, and liver (Fig. 2C,D; data not shown).
Immunophenotyping, cytologic, and histologic analyses
revealed that AML1/ETO9a + Nras leukemias predomi-
nantly contain immature blasts (Mac1, Gr1, Ly-6C,
F4/80/lo, CD45lo, CD3, CD19, B220, TER119,
c-Kit+, Sca-1) (Fig. 2B,C; data not shown), which parallels
observations in other models of core factor-binding AML
(Yan et al. 2004; Kuo et al. 2006). Although such purely
immature subtypes are seen in t(8;21)-positive AML,
most human cases show a significant granulocytic mat-
uration beside immature myeloblasts, which was absent
in murine AML1/ETO9a + Nras AML. In contrast, MLL/
ENL + Nras leukemias predominantly consisted of more
differentiated myeloid cells (Mac1+, Gr1+/lo, Ly-6C+, F4/
80+/lo, CD45+, CD3, CD19, B220, TER119, c-Kit/lo,
Sca-1) (Fig. 2B,C; data not shown) and involve the
monocytic lineage—a typical feature of human 11q23-
rearranged AML. As in previous MLL fusion-based mouse
models (Cozzio et al. 2003), the morphology resembles
myelomonocytic and monocytic subtypes, which are
seen in ;42% of human 11q23-rearranged AML (Schoch
et al. 2003). Despite its potent effects on leukemia onset,
Nras did not appear to influence leukemia morphology,
since leukemias induced by AML1/ETO9a or MLL/ENL
alone were similar to those coexpressing Nras. In sum-
mary, mosaicmousemodels based on cooperation of Nras
with either fusion protein recapitulate common genetic
and pathologic features of human AML.
Establishment of a murine chemotherapy regimen that
mimics clinical AML induction therapy
To study factors that influence the outcome of conven-
tional AML therapy in mice, we established a simple
chemotherapy regimen involving intraperitoneal (i.p.)
injection of cytarabine (100 mg/kg per day over 5 d) and
doxorubicin (3 mg/kg per day over 3 d) (Supplemental Fig.
S1A), which mimics the standard induction therapy used
to treat AML in human patients. In initial toxicity
studies, cytarabine doses of 50 and 100 mg/kg per day
weremyelosuppressive but well tolerated over a 7-d treat-
ment course (Supplemental Fig. S2A). Administration of
100 mg/kg cytarabine intraperitoneally resulted in
plasma levels in the range of human high-dose cytarabine
regimens (Supplemental Fig. S2B; Hiddemann 1991). A
consistent drug delivery in different animals and leuke-
mia genotypes was verified using flow cytometry quanti-
fication of intracellular doxorubicin (Supplemental Fig.
S2C). Of note, doxorubicin was used instead of daunoru-
bicin, which is the more common anthracycline in
human AML therapy, but resulted in severe toxicity if
administered intraperitoneally in mice (data not shown).
The efficacy and safety of the combined regimen were
initially evaluated in a pre-existing model based on
cotransduction of MLL/ENL and FLT3-ITD (Ono et al.
2005) and were later applied to models established in this
study. In order to rapidly generate homogenous treatment
cohorts, we harvested bone marrow and spleen from
terminally ill primary FLC recipient mice and trans-
planted 1 million leukemia cells into 20–30 secondary
recipients. In initial studies, we observed that this com-
bination therapy was not tolerated in mice when treat-
ment was initiated based on a high leukemia burden in
the peripheral blood; although the peripheral disease
disappeared within 2 d, animals died shortly thereafter
with peripheral leukopenia (data not shown).
To better monitor leukemia progression and treat ani-
mals at an earlier stage of disease,we took advantage of the
luciferase reporter, which we linked to MLL/ENL in a
bicistronic retrovirus (MSCV-MLL/ENL-IRES-Luciferase).
Bioluminescent imaging allowed detection ofMLL/ENL +
FLT3-ITD leukemic cells inbonemarrow, spleen, and liver
;10 d after transplantation into secondary recipients,
which corresponded to;30% infiltration in bonemarrow
and spleen in pathologic analysis, while the disease
became apparent in peripheral blood smears ;5–7 d later
(Supplemental Fig. S1C; data not shown). When mice
were treated when disease was detected by biolumines-
cent imaging, most showed some response to therapy
(Supplemental Fig. S1B), while untreated controls pro-
gressed rapidly (Supplemental Fig. S1C). Although most
responseswere only partial (median survival benefit of 7 d,
Zuber et al.
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P < 0.0001) (Supplemental Fig. S1D), none of the animals
appeared to succumb to treatment toxicity, but instead
from advancing leukemia. These studies demonstrate the
utility of bioluminescencemonitoring for treatment stud-
ies and establish an effective and safe combined chemo-
therapy regimen that mirrors human AML induction
therapy.
AMLs expressing AML1/ETO9a or MLL/ENL display
differences in response to conventional chemotherapy
To determine whether defined AML genotypes display
distinct treatment sensitivities, we transplanted multiple
primary AML1/ETO9a + Nras and MLL/ENL + Nras
leukemias and treated secondary recipient mice upon
bioluminescent disease detection in bone marrow and
spleen. Leukemias coexpressing AML1/ETO9a and Nras
rapidly regressed under combined chemotherapy, leading
to complete remissions. Thus, by 6 d after initiating
treatment, luciferase signals disappeared completely,
and histological analyses and flow cytometry revealed
that the bone marrow and spleen were leukemia-free
(Figs. 3A, 6C [below]; data not shown). In most instances,
mice harboring these leukemias remained in remission
for at least 30 d (Fig. 3C), showing an overall survival
benefit of 69 d (P < 0.0001) (Fig. 3D). Although 80% of the
treated mice eventually relapsed, often emanating from
focal regions in bones or spleen, the rest remained
leukemia-free for even 1 yr. Such behavior is reminiscent
of the generally effective action of induction therapy in
patients.
In stark contrast, MLL/ENL + Nras-induced AML
persisted under chemotherapy, and bioluminescent imag-
ing merely showed a decelerated progression. In addition
to apoptotic cell death, histological analysis revealed
refractory leukemic infiltrates in bonemarrow and spleen
(Fig. 3B). After a minor stagnation in disease acceleration,
all treated animals progressed rapidly and died with only
a minor survival benefit (5 d compared with untreated
controls, P < 0.0001) (Fig. 3D). Hence, the MLL/ENL
fusion protein produced leukemias that showed a very
poor therapeutic response.
p53 contributes to genotype-specific differences
in chemotherapy response
As a first step toward understanding the differential
response of leukemia genotypes to therapy, we performed
microarray analysis on leukemias expressing AML1/
ETO9a + Nras or MLL/ENL + Nras following combined
cytarabine/doxorubicin therapy in vivo. Two indepen-
dent primary leukemias of each genotype were trans-
planted into multiple recipients, and diseased animals
were either left untreated or treated with a single dose of
cytarabine and doxorubicin. Two hours following treat-
ment, spleens were isolated and subjected to transcrip-
tional profiling using Affymetrix Mouse Genome 430 2.0
arrays. AML1/ETO9a + Nras leukemias induce complex
gene expression changes immediately upon chemother-
apy (greater than twofold change in 418 genes), while
MLL/ENL + Nras AMLs showed much less transcrip-
tional alterations in response to treatment (greater than
twofold alteration in only 33 genes, 15 in common
with AML1/ETO9a + Nras) (Fig. 4A). Using Significance
Analysis of Microarrays (SAM) with the criteria of a false-
discovery rate (FDR) of #0.20 and an average fold change
of $2.0 (Tusher et al. 2001), we identified an immediate
drug response signature comprising 226 up-regulated
and 172 down-regulated genes in AML1/ETO9a + Nras
Figure 2. Defined mosaic AML mouse models have genotype-
dependent morphology consistent with human AML. May-
Gru¨nwald-Giemsa-stained peripheral blood smears (A) (original
magnification 2003) and Wright-Giemsa-stained bone marrow
cytocentrifugation (B) (original magnification 10003) predomi-
nantly show immature blasts in AML1/ETO9a +Nras leukemia,
while MLL/ENL + Nras leukemia is characterized by more
mature myelomonocytic cells at various differentiation levels.
(C) Bone marrow immunphenotyping in AML1/ETO9a + Nras
leukemic mice shows infiltration of GFP+/c-Kit+/Mac-1/Gr-1
immature blasts, while MLL/ENL + Nras bone marrow is
dominated by GFP+/c-Kit/lo/Mac-1+/Gr-1+ myelomonocytic
cells. (D) Hematoxylin–eosin-stained liver sections showing
massive leukemic infiltration. Bars, 100 mm.
Mouse models of human AML therapy
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leukemias that was largely absent in treated MLL/ENL +
Nras leukemia. Unsupervised clustering using this sig-
nature clearly separated both AML subtypes and identi-
fied subclusters distinguishing untreated and treated
AML1/ETO9a + Nras samples; however, there was
no such separation between untreated and treated MLL/
ENL + Nras AMLs (Supplemental Fig. S3).
To further characterize this expression signature we
performed KEGG pathway analysis (Ogata et al. 1999)
to identify processes that are specifically altered in re-
sponse to chemotherapy. Only five out of 195 analyzed
pathways showed significant (P < 0.001) alteration 2 h
after chemotherapy (Fig. 4B). Interestingly, the most
significantly altered category involved genes associated
with the p53 signaling network (P = 1.79E-09), which
has been implicated as a central component in DNA
damage response programs and whose integrity can
contribute to the efficacy of chemotherapeutic agents
(Lowe et al. 1993; Schmitt et al. 2000). Several well-
characterized transcriptional p53 target genes such as
Cdkn1a (p21), Mdm2, Apaf1, and Ccng1 showed strong
induction in treated AML1/ETO9a + Nras leukemia,
while their alteration was weaker or not detected in
treated MLL/ENL + Nras AML. Through immunoblot-
ting and/or RT–QPCR analyses on leukemia lysates
from untreated and treated animals, we confirmed that
the therapy-induced accumulation of p53 and two of
its target genes (p21 and Mdm2) were strongly attenuated
in MLL/ENL + Nras leukemias relative to those
expressing AML1/ETO9a + Nras (Fig. 4C,D). In addition
to these dramatic differences after chemotherapy, MLL/
ENL-expressing leukemias show lower p21 levels already
in the untreated state, which might indicate a lower
p53 baseline activity. These differences in p53 function-
ality were observed in multiple primary leukemias
of each genotype (Fig. 4E; data not shown). Of note,
genes encoding drug transporters, drug modifiers, and
efflux pumps implicated in cytarabine and doxorubicin
resistance such as Abcb1 (Mdr1), Abcc1 (Mrp1), Slc29a1
(hENT1), Dck, and Cda (Galmarini et al. 2002) were not
dysregulated in MLL/ENL-expressing leukemias, and we
did not detect any genotype-dependent differences in
the intracellular accumulation of doxorubicin in vivo
(Supplemental Fig. S2C). Thus, while p53-independent
mechanisms undoubtedly influence treatment sensitiv-
ity, the inability of MLL-rearranged leukemias to mount
an effective p53 response may be a major factor contrib-
uting to their intrinsic chemotherapy resistance.
Figure 3. AML1/ETO9a + Nras and MLL/ENL
+ Nras AMLs show dramatic differences in their
response to combined chemotherapy in vivo.
(A,B) Luciferase imaging and histological analy-
sis of hematoxylin–eosin-stained bone marrow
sections before (d0), during (d3), and after (d6)
5 d of chemotherapy show therapy-triggered
regression and, ultimately, complete remission
of AML1/ETO9a + Nras leukemia (A), while
MLL/ENL + Nras leukemia (B) only shows de-
celerated progression, with persistence of blasts
in response to treatment. Bars, 50 mm. (C) Long-
term follow-up luciferase imaging of untreated
and treated AML1/ETO9a + Nras leukemia.
Treated mice achieve durable remissions lasting
at least 30 d (d30). While most mice subse-
quently relapse, some mice remain in remission
following chemotherapy (d60). (D) Kaplan-Meier
survival curves of untreated and treated AML1/
ETO9a + Nras and MLL/ENL + Nras mice
following the initiation of chemotherapy.
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Impact of p53 on leukemogenesis and therapy response
p53 is a central component in tumor suppressor networks
that enable cells to evade malignant transformation by
triggering fail-safe programs such as apoptosis or senes-
cence in response to oncogene activation (for review, see
Vogelstein et al. 2000; Lowe et al. 2004). To further study
how p53 impacts AML leukemogenesis in the context of
different oncogenic fusion proteins, we engineered mu-
rine AMLs lacking p53. Wild-type and p53/ FLCs were
transduced with retroviruses expressing AML1/ETO9a or
MLL/ENL and transplanted into lethally irradiated recip-
ients. p53 loss had a dramatic impact on leukemogenesis
induced by AML1/ETO9a, leading to the appearance of
AML with a significantly shortened overall survival
(69 vs. 170 d, P < 0.0001) (Fig. 5A). Indeed, while the
morphology and immunophenotype of AML1/ETO9a-
induced leukemias were not affected by loss of p53 (Fig.
5B), their behavior paralleled the more rapid onset and
aggressive nature of leukemias expressing MLL/ENL. In
contrast, p53 loss had no impact on leukemogenesis
induced by MLL/ENL, with leukemias showing an onset
and morphology indistinguishable from wild-type MLL/
ENL controls. It is noteworthy that, in our experience,
MLL/ENL is the only AML oncogene that does not co-
operate with p53 loss in promoting leukemia, while AML
induced by lesions such as NrasG12D, KrasG12D, FLT3-ITD,
full-length AML1/ETO, Pten loss, or Nf1 loss is accelerated
by the absence of p53 (J. Zuber, Z. Zhao, A.R. Rappaport,
and S.W. Lowe, unpubl.). Apparently, MLL/ENL enables
cells to evade the p53 network during leukemogenesis.
Beyond its role as classical tumor suppressor, studies
indicate that inactivating p53 mutations confer resis-
tance to chemotherapy in some animal models (Schmitt
et al. 1999) and to cytarabine treatment of AML cell lines
in vitro (Yin et al. 2006). Moreover, loss of p53 has been
associated with poor treatment outcome in patients, in-
cluding in AML (Wattel et al. 1994; Haferlach et al. 2008).
To experimentally evaluate the impact of dysfunctional
p53 on chemotherapy response, we generated AML1/
ETO9a + Nras leukemias derived from p53/ FLCs and
compared their behavior with p53-expressing leukemias
following induction therapy. Again, primary recipient
mice developed AMLs that were morphologically similar
to their p53 wild-type counterparts (data not shown), but
showed accelerated disease progression (median survival
44 vs. 84 d, P < 0.0001) (Fig. 5C). Treatment of these
primary leukemias in secondary recipients was performed
as above, with bioluminescent imaging as a guide for
initiating treatment and monitoring therapy response.
Figure 4. In vivo expression analysis of immediate chemother-
apy response programs identifies differences in p53 induction
between AML1/ETO9a + Nras and MLL/ENL + Nras AMLs. (A)
Chemotherapy-induced gene expression changes in AML1/
ETO9a + Nras and MLL/ENL + Nras leukemias 2 h after
combined chemotherapy rendered in a green–black–red pseudo
color scheme for all genes with an average fold change $2.0 in
either genotype. Samples included two independent primary
leukemias (1,2) for each genotype, which were analyzed in two
technical replicates (a,b). AML1/ETO9a + Nras leukemias show
complex gene expression changes in response to chemotherapy,
while this response profile is blunted in the MLL/ENL + Nras
context. (B) KEGG pathways analysis (Ogata et al. 1999) of the
AML1/ETO9a + Nras-specific chemotherapy response signature
identified by SAM (FDR 0.2, fold change >2). Used P-values
represent the EASE score (modified Fisher exact P-value) pro-
vided by the DAVID analysis tool (Dennis et al. 2003) available
at http://david.abcc.ncifcrf.gov/summary.jsp. Two highly and
three moderately significant pathway alterations are identified.
(C) Quantitative real-time PCR analysis of p21 and Mdm2 at
various time points after chemotherapy in vivo. Baseline ex-
pression and induction of both p53 target gene transcripts is
attenuated in MLL/ENL + Nras leukemia. (D) Western blot
analysis of p53 and p21 in leukemic spleens (>85% GFP+
infiltration) at various time points after i.p. administration of
one dose of combined chemotherapy. AML1/ETO9a + Nras
AML showsmuch stronger p53 induction, resulting in a stronger
and more durable induction of its target p21. (E) Western blot
analysis of p53 and p21 in recipient mice that were transplanted
with independent primary AMLs and were either left untreated
() or were treated with one dose of combined chemotherapy 4 h
prior to sample harvest (+). Individual differences in p53 drug
response programs are dependent on the AML genotype.
Mouse models of human AML therapy
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In contrast to their p53 wild-type counterparts, p53/
leukemias expressing AML1/ETO9a + Nras responded
poorly to induction chemotherapy. Using all diagnostic
modalities, including luciferase imaging (Fig. 6A), histol-
ogy (Fig. 6B), and bone marrow flow cytometry for GFP-
positive leukemic cells (Fig. 6C), mice harboring p53-null
leukemias demonstrated blast persistence and gained
only a minor survival benefit from therapy (10 d survival
benefit, P = 0.0001). In no cases were animals cured.
These observations are in striking contrast to the strong
survival benefit and 20% cure rate observed in AML1/
ETO9a +Nras counterparts harboring intact p53 (Fig. 6D;
see also Fig. 3). Thus, in the absence of p53, leukemias
expressing AML1/ETO9a show a poor treatment response
approaching that seen forMLL/ENL-expressing leukemias.
These results demonstrate thatmodulation of p53 activity,
whether through inhibition in the context of MLL/ENL or
via gene deletion, has an important impact on the response
of murine AMLs to conventional chemotherapy.
Discussion
In this study, we use mice harboring leukemias that
accurately reflect the genetics and pathology of human
AML as tractable models to study the impact of cancer
heterogeneity on therapy response and to explore the
molecular basis for variable leukemia behavior. We see
that leukemias expressing the AML1/ETO9a oncoprotein
[mimicking translocation (8;21) in humans] respond well
to conventional chemotherapy, whereas those expressing
MLL/ENL [recapitulating translocation (11;19) in humans]
show a particularly dismal response. Remarkably, the re-
sponse patterns of these two leukemia subtypes accu-
rately mimic what is observed in human patients with
the same genetic lesions. These results provide important
insights into the clinical behavior of human AML and
highlight the utility of genetically engineered mouse
models as predictive models for therapy in patients.
Initially using genome-wide transcriptional profiling of
treatment responses in vivo, we identified a gene expres-
sion signature in drug-sensitive AML1/ETO-expressing
leukemias that was absent in drug-resistant leukemias
expressing MLL/ENL. The most significant element of
this signature involved strong alterations in genes linked
to the p53 tumor suppressor network. Indeed, further
evaluation of leukemia samples at various time points
after chemotherapy demonstrated that the excellent re-
sponse of AML1/ETO-expressing leukemias requires a
robust activation of the p53 network, whereas poorly
responding MLL/ENL leukemias show a dramatic atten-
uation of the p53 response. How this eventually leads to
leukemia cell clearance remains to be determined, and,
based on our gene expression and preliminary histological
analyses (data not shown), may involve a combination of
p53 effector functions. Although the impact of MLL/ENL
on p53 may be indirect, previous cell culture studies
suggest that MLL fusion proteins can associate with p53
and prevent its acetylation and activation following DNA
damage (Wiederschain et al. 2005). While these observa-
tions derive from studies in cultured carcinoma and
osteosarcoma cells, our data indicate that such p53-
suppressive effects of MLL fusion proteins can occur in
AML cells and contribute to chemotherapy resistance in
an in vivo context.
Figure 5. Loss of p53 dramatically accelerates AML1/ETO9a,
but does not affect MLL/ENL-induced leukemogenesis. (A)
Kaplan-Meier survival curves of lethally irradiated recipient
mice, which were reconstituted with wild-type or p53/ FLCs
transduced with either AML1/ETO9a or MLL/ENL. Loss of p53
accelerates AML1/ETO9a-induced but not MLL/ENL-induced
leukemogenesis. (B) Bone marrow immunophenotyping of wild-
type and p53-deficient AML1/ETO9a- and MLL/ENL-induced
leukemias. Loss of p53 does not affect the typical disease
morphology induced by both fusion proteins. (C) Kaplan-Meier
survival curves of lethally irradiated recipient mice, which were
reconstituted with wild-type or p53/ FLCs cotransduced with
AML1/ETO9a and NrasG12D. Loss of p53 also accelerates AML1/
ETO9a + Nras-induced leukemogenesis.
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In addition to its role in chemotherapy responses, p53 is
a potent tumor suppressor that is lost in the majority of
human epithelial cancers prior to treatment (Petitjean
et al. 2007). Mutations in other genes that modulate p53
function can also occur during tumorigenesis, which
allows aggressive tumors to arise in the presence of
wild-type p53. Beside attenuating p53 activation follow-
ing chemotherapy, MLL fusion proteins also seem to
interfere with tumor-suppressive functions of p53 during
myeloid leukemogenesis. In fact, in our experience, MLL
fusion proteins are the only AML oncogenes that do not
show increased leukemogenic potential in the absence of
functional p53 (see Fig. 5; data not shown). Consistent
with this, some studies report that MLL rearrangements
and p53 mutations rarely co-occur in human AML
(Megonigal et al. 1998; Haferlach et al. 2008). In contrast,
in patients, p53 mutations exist in AML1/ETO and
inv(16) AML and correlate with relapse and treatment
resistance (Krejci et al. 2008). In fact, in mice we see that
AML1/ETO-expressing leukemias lacking p53 show
a similar aggressiveness and chemoresistance to those
expressing MLL/ENL. Therefore, while p53 is mutated or
deleted in only 13% of all AML patients (Haferlach et al.
2008), its functional attenuation by MLL fusion proteins
represents an alternative way through which p53 net-
works can be impaired in AML. This inherent inhibition
of p53 tumor suppressor networks may be an important
element involved in the transforming potential of MLL
fusion proteins.
Our studies also have implications for the clinical
treatment of human AML. Although correlative studies
in human patients have linked various MLL transloca-
tions (Schoch et al. 2003) and p53 mutations (Wattel et al.
1994) to poor prognosis, this information is not com-
monly used in guiding current AML treatment regimens.
By showing that MLL/ENL expression or mutation of p53
can severely compromise therapy outcome in animal
models, our studies provide direct in vivo evidence that
these lesions play a causal role in promoting drug re-
sistance. As such, the functional validation of these
resistance-promoting alleles, together with the corre-
sponding clinical data, justifies the use of these markers
in patient management. For example, when extrapolated
to the human condition, our data suggest that AML
patients diagnosed with MLL/ENL rearrangements or
p53 mutations will not show durable responses to stan-
dard chemotherapy and should be offered alternative
approaches at diagnosis—perhaps more aggressive/exper-
imental regimens or palliative care, depending on the
individual case. Furthermore, our data provide functional
support for the notion that, irrespective of genotype, the
robustness of the p53 network activation following che-
motherapy is the single most important determinant of
outcome to conventional chemotherapy in AML. Indeed,
Figure 6. Loss of p53 induces chemotherapy resistance in AML1/ETO9a + Nras AML. (A) Luciferase imaging of AML1/ETO9a + Nras
leukemias generated in wild-type (left panel) or p53/ (right panel) FLCs before (d0), during (d3), and after (d6, d24) chemotherapy.
Recipient mice of p53-deficient AML1/ETO9a + Nras leukemias retain bioluminescent signal under therapy. (B) Hematoxylin–eosin-
stained bone marrow sections of recipients of p53-deficient AML1/ETO9a + Nras leukemia at various time points following
chemotherapy, demonstrating leukemia persistence during chemotherapy. Bars, 50 mm. (C) GFP histograms of bone marrow flow
cytometry before (d0) and at various time points during (d3) and after (d6, d9) chemotherapy. While AML1/ETO9a + Nras blasts
harboring wild-type p53 (AE + Nras p53 wt) rapidly clear, both MLL/ENL + Nras (ME + Nras p53 wt) and p53-deficient AML1/ETO9a +
Nras leukemias (AE + Nras p53/) show persistence of GFP+ cells in bone marrow. (D) Kaplan-Meier survival curves of untreated and
treated recipient mice of p53 wild-type and p53-deficient AML1/ETO9a + Nras leukemias. Loss of p53 impedes the long-term outcome
of chemotherapy.
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studies support the technical feasibility and potential
value of assessing p53 activation during the first hours of
therapy in patients (Anensen et al. 2006).
Our studies also have important implications for the
use of genetically engineered mouse models in preclinical
studies. In principle, genetically engineered mouse mod-
els of human cancer provide the opportunity to study
therapy responses of genetically defined cancers in a rel-
evant pathophysiologic context that cannot be reca-
pitulated in vitro or in xenotransplantation settings.
Nevertheless, human and murine cells have documented
differences in certain oncogenic signaling pathways,
stress response programs, and drug pharmacology that
may impact how tumors respond to a particular drug or
drug combination (Van Dyke and Jacks 2002; Sharpless
and Depinho 2006). Consequently, there has been much
debate as to whether mouse models of human cancer can
be predictive of therapy response in vivo.
A key impediment in ‘‘credentialing’’ genetically engi-
neered mouse models as reliable preclinical systems for
studying therapeutic response is the paucity of compara-
ble mouse and clinical data for a given drug and drug
combination. By studying the effects of conventional
chemotherapy in genetically engineered mouse models
of AML, we not only uncover factors that influence the
outcome of a clinically important treatment regimen, but
also address the predictability of mouse models using
outcome data obtained through decades of clinical expe-
rience. Our studies find a remarkable similarity in the
genotype response pattern of mouse AML models and
human AML patients to standard induction chemother-
apy, implying that such systems can predict the behavior
of therapeutic agents in the clinic. Therefore, these and
similar mouse models provide relevant systems for fur-
ther studies on drug action and drug resistance and, by
extrapolation, predictive test systems for evaluating new




All retroviruses were constructed in the MSCV backbone (Clon-
tech). MSCV-IRES-Luciferase was generated by replacing GFP in
MSCV-IRES-GFP with an NcoI/SalI fragment from pGL3-Basic
(Promega) after excision of the 39polyA signal. Mouse NrasG12D
was amplified and mutated by PCR from IMAGE clone 6475312
(Invitrogen) and cloned downstream from the IRES; subsequently
Luciferase was cloned upstream of the IRES. The AML1/ETO9a
cDNA was generated by PCR from full-length human AML1/
ETO-IRES-GFP and subcloned into MSCV-IRES-GFP. Human
MLL/ENL was subcloned from MLL/ENL-PGK-Neo (generously
provided by Irving L. Weissman) into MSCV-IRES-GFP and
MSCV-IRES-Luciferase. Human FLT3-IRES-YFP and AML1/
ETO-IRES-GFP were kindly provided by Christian Buske. Clon-
ing strategies and primer sequences are available on request.
FLC isolation, retroviral transduction, and transplantation
The Cold Spring Harbor Animal Care and Use Committee
approved all mouse experiments included in this work. E13.5–
E15 FLCs from wild-type C57BL/6 mice were isolated, cultured,
and retrovirally transduced as described previously (Schmitt
et al. 2002). Retroviral cotransduction was carried out by mixing
viral supernatants from independent transfections of Phoenix
packaging cells in a 1:1 ratio. Retroviral transduction of GFP-
expressing constructs was assessed 24 h after the last infection by
flow cytometry (Guava EasyCyte, Guava Technologies), typically
demonstrating transduction of ;20% of FLCs. Transduction
of luciferase-expressing constructs was confirmed qualitatively
(IVIS100, Caliper LifeSciences). About 1 3 106 cells were trans-
planted by tail vein injection of 6- to 8-wk-old lethally irradiated
C57BL/6 recipient mice (9.0 Gy as single dose administered 24 h
prior to transplantation).
Monitoring and characterization of primary leukemias
Bioluminescent imaging was performed using an IVIS100 imag-
ing system (Caliper LifeSciences). Mice were injected intraperi-
toneally with 150 mg/kg D-Luciferin (Caliper LifeSciences),
anesthetized with isoflurane, and imaged for 1 min after
a 5-min incubation following injection. Primary FLC recipient
mice were sacrificed at terminal disease stage (whole-body signal
in bioluminescent imaging, severe leukocytosis in peripheral
blood smears, moribund appearance) by CO2 euthanasia. Statis-
tical evaluation of overall survival was based on the log-rank
(Mantel-Cox) test for comparison of the Kaplan-Meier event time
format. Leukemia cells were harvested from bone marrow (by
flushing tibias and femurs with DMEM) and spleen (by gently
meshing enlarged spleens in DMEM between two glass slides),
filtered through 100-mm cell strainers (BD Falcon) to obtain
single-cell suspensions, and cryopreserved in fetal bovine serum
(FBS) containing 10% DMSO. Peripheral blood smears and bone
marrow cytospins were stained with Wright-Giemsa (Sigma);
tissue specimens were fixed in 10% formalin and stained with
hematoxylin and eosin (Sigma) using standard protocols. For
immunophenotyping, single-cell suspensions of bone marrow
and spleen were incubated in ACK red cell lysis buffer (150 mM
NH4Cl, 10 mM KHCO3, 0.1 mM EDTA) for 5 min, resuspended
in FACS buffer (PBS, 5%FBS, 0.1%NaN3), and preincubated with
anti-CD16/CD32 (Fc-block, 1:1000; BD Pharmingen). Aliquots of
2 3 105 to 5 3 105 cells were stained for 20 min on ice with
phycoerythrin-Cy5-conjugated monoclonal antibodies specific
for Mac-1, Gr-1, F4/80, CD45, CD3, CD19, B220, TER119,
c-Kit, Sca-1, and a phycoerythrin-conjugated Ly-6C antibody
(all 1:100; Biolegend). Data were collected on an LSR-II flow
cytometer (BD Biosciences) and analyzed using FACSDiva (BD
Biosciences) and FlowJo (Treestar) software.
Transplantation and in vivo treatment studies
For treatment studies, each primary leukemia was transplanted
into 20–30 6- to 8-wk-old sublethally irradiated recipient mice
(4.5 Gy, 24 h prior to transplantation) by tail-vein injection of 13
106 viable GFP+ cells per recipient. Sublethal irradiation was
used to achieve a more uniform disease onset in recipient
animals. Recipient mice were maintained on Ciprofloxacin-
supplemented drinking water (Ciprofloxacin 125 mg/L, sucrose
20 g/L; both Sigma) until 2 wk after the end of chemotherapy.
This antibiotic regimen has been shown to efficiently decon-
taminate aerobic Gram-negative pathogens without major
effects on hematopoiesis (Velders et al. 2004). Mice were mon-
itored by bioluminescent imaging every 4 d, starting 10 d after
transplantation. Chemotherapy was initiated upon detection of
clear signals in pelvis, tail, and both femurs, and initial stage of
hepatosplenic infiltration, which correlated with 30%–60%
bone marrow infiltration as assessed by flow cytometry. Mice
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were treated for five consecutive days every 24 h with i.p.
injections of 100 mg/kg cytarabine (Bedford Laboratories); during
the first 3 d, 3 mg/kg doxorubicin (Bedford Laboratories) was
administered in a separate i.p. injection. Immediate response and
long-term treatment effects weremonitored by weekly luciferase
imaging starting the first day after treatment and by histopath-
ological analysis of representative mice at various time points.
Details of HPLC cytarabine plasma level analysis and flow
cytometry measurement of intracellular doxorubicin can be
found in the Supplemental Material.
Gene expression analysis (quantitative real-time PCR,
microarrays, and immunoblotting)
Fordrug response studies, diseasedmicewere treatedwitha single
dose of cytarabine (100 mg/kg) and doxorubicin (3 mg/kg) i.p. at
various time points prior to harvest. Samples were obtained from
enlarged spleens predominantly containing leukemia cells; in-
filtration of >85% GFP+ cells was confirmed by flow cytometry.
Following ACK-lysis of single-cell suspensions, RNA was
extracted using RNAeasy columns (Qiagen) and cDNA was
synthesizedusingTaqManreverse transcriptase reaction (Applied
Bosystems) according to the manufacturer’s protocols. Quantita-
tive PCR analysis was performed on an iCycler mounted with an
iQ5 multicolor real-time PCR detection system (Bio-Rad). Ex-
pression data were normalized against b-actin controls. For
primer sequences, see the Supplemental Material. Microarray
experiments were performed on Mouse Genome 430A 2.0 arrays
(Affymetrix) according to the manufacturer’s instructions. For
Western blot analysis, ACK-treated samples were lysed in
Laemmli buffer, separated by SDS-PAGE, and transferred to
Immobilon PVDF membrane (Millipore). We used antibodies
against p53 (IMX25, 1:1000; Leica Microsystems), p21 (C-19,
1:500; SantaCruz Biotechnologies), Nras (F155, 1:300; SantaCruz
Biotechnologies), pan-Ras (Ras10, 1:1000; Upstate Biotechnolo-
gies), andActin (AC-15, 1:5000; Abcam). Flow cytometry analysis
of phospho-Erk in bone marrow was performed using anti-pERK
(#9101, C1:100; ell Signaling) as described previously (Van Meter
et al. 2007). To assess baseline phospho-Erk levels, cells were
starved in serum-free medium for 30 min at 37°C. and then fixed
and analyzed without cytokine stimulation.
Microarray data analysis
Raw data were processed using FARMSmethod (Hochreiter et al.
2006) with an up-to-date probe set definition based on Entrez
gene sequences (Dai et al. 2005). Treated versus untreated
samples were analyzed in biological (independent primary leu-
kemias) and technical replicates using a one-on-one comparison
scheme. We used SAM (Tusher et al. 2001) with an FDR of#0.20
and an average fold change of$2.0 as selective criteria to identify
a drug response signature. Significantly perturbed KEGG path-
ways (Ogata et al. 1999) were identified using the functional
annotation tool available at DAVID (http://david.abcc.ncifcrf.-
gov/summary.jsp) (Dennis et al. 2003).
Acquisition and analysis of human data
One-hundred-eleven pediatric AML cases treated at St. Jude
Children’s Research Hospital (SJCRH) between 1982 and 2005
were studied. Informed consent for the use of samples was
obtained from patients, parents, or guardians in accordance with
the Declaration of Helsinki. Study approval was obtained from
the SJCRH institutional review board. Mononuclear cells were
purified from diagnostic bone marrow or peripheral blood sam-
ples by density gradient centrifugation. DNAwas extracted using
the DNA Blood Mini Kit (Qiagen). NRAS exons 1 and 2 were
amplified from genomic DNA using Accuprime GC-rich Poly-
merase (Invitrogen). For primer sequences see the Supplemental
Material. Overall survival was defined as the time elapsed from
study enrollment to death, with those still living at last follow-
up considered censored. The Kaplan-Meier method was used to
estimate the probability of overall survival and standard errors
were determined by the method of Peto and Pike. The overall
survival comparisons among subtypes were performed by Man-
tel-Haenszel log-rank test stratified by protocol. overall survival
was studied for cases treated after 1998 and included 16 AML97,
30 AML02, and four nonprotocol patients. Significance of the
association of Nras mutations with cytogenetic subtypes was
analyzed by multifactor dimensionality reduction (Ritchie et al.
2001); see the Supplemental Material for details.
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